Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 30, Issue 2, 2003, Pages 225-231

  Cohen, Stanley B ^a,b   Woolley, J Michael ^a,b   Chan, Wing W ^a,b  

^a University Hospital St Paul Medical Center   (United States)

^b AMGEN INC   (United States)

Author keywords

Anakinra; Functional status; Health assessment questionnaire; Interleukin 1 receptor antagonists; Quality of life; Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EATING; FEMALE; FUNCTIONAL ASSESSMENT; GROOMING; HUMAN; HYGIENE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHEUMATOID ARTHRITIS; WALKING;

ACTIVITIES OF DAILY LIVING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SIALOGLYCOPROTEINS; TREATMENT OUTCOME;

EID: 0037309790     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Group for the Respect of Ethics and Excellence in Science (GREES): rheumatoid arthritis section. Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. Br J Rheumatol 1998;37:211-5.
2. Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol 2001;15:139-70.
3. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
4. Hughes LB, Moreland LW. New therapeutic approaches to the management of rheumatoid arthritis. BioDrugs 2001;15:379-93.
5. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33:305-15.
6. Cohen S, Hurd E, Cush JJ, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
7. Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology Huntingt 1990;4:29-38.
8. Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press; 1993.
9. Pincus T, Callaban LF. Early mortality in RA predicted by poor clinical status. Bull Rheum Dis 1992;41:1-4.
10. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44:1234-6.
11. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
12. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
13. Goldsmith C, Boers M, Bombardier C, Tugwell P for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. J Rheumatol 1993;20:581-5.
14. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
15. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data [review]. Stat Med 1997;16:2349-80.
16. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology Oxford 2000;39:655-65.
17. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
18. Maini R, St. Clair EW, Breedveld F, et al, the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
19. Cohen S, Nakelsky S, Mulani P, et al. The impact of anakinra therapy on patient-centered outcomes in rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44 Suppl:S77.
20. Cohen S, Smolen J, Tugwell P, Crawford B, for the Leflunomide Study Group, Strand V. Patient-based functional measures of drug treatment in rheumatoid arthritis trials are not susceptible to placebo effect [abstract]. Arthritis Rheum 2000;43 Suppl:S288.
21. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life: Sensitivity and relative efficiency to detect a treatment effect in a 12-month placebo controlled trial comparing leflunomide with methotrexate. Arthritis Rheum 2000;43:506-14.
22. Pincus T, Wolfe F, Strand V, Kavanaugh A, Crawford B, Felson D. Patient questionnaire data discriminate between drug vs placebo as effectively as the ACR20 in a clinical trial of patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 Suppl:S288.
23. Singh G. Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program. J Rheumatol 2001;28:1174-9.